Back

LDL-C reducing agents; what genetic tells us

1 September 2019 (13:27 - 13:45)
Organised by:
Congress Presentation Part of: Hypercholesterolemia management - What will be our options after tomorrow? Pharmacogenetics ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
To be or not to be…but at which goal?
Professor L. Tokgozoglu (Ankara, TR)
Slides Video
Presentation thumbnail
Combination therapy in CV risk reduction: what are we waiting for in dyslipidaemia management?
Professor P. Steg (Paris, FR)
Slides Video
Presentation thumbnail
Getting to goals cost effectively, how can we make a difference?
Professor E. Stroes (Amsterdam, NL)
Slides Video

Access the full session

Session thumbnail
Hypercholesterolemia management - What will be our options after tomorrow?

The Event

Event poster

ESC Congress 2019

1 September 2019 13:27 CET
You may be interested in
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions
thumbnail
Congress Presentation
Pharmacogenetics for mavacamten treatment individualization in patients with obstructive hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources